What this opportunity is
The Department of Veterans Affairs intends to sole source a contract for the Signos Continuous Glucose Monitoring technology with an AI-driven mobile application platform, a non-pharmacological intervention for weight management and metabolic health among Veterans. This pilot is set aside for small businesses under NAICS code 518210, Telecommunications Resellers. As a Special Notice, this opportunity does not require a formal solicitation, and interested small businesses should track the announcement for updates.
Analysis by Mindy, grounded in the SAM.gov notice.
Description
Performance Work Statement DRAFT
Purpose
The Veterans Health Administration seeks to evaluate the Continuous Glucose Monitoring
technology with an AI driven mobile application platform as a potential
non-pharmacological intervention to support weight management and metabolic health
among Veterans. This pilot is intended to address the needs of individuals who are not
eligible for, have not responded to, or prefer to avoid pharmacologic treatments such as
GLP-1 receptor agonists. The initiative will assess the feasibility and effectiveness of
integrating Continuous Glucose Monitoring technology with an AI-driven mobile
application to deliver real-time insights, support behavior change, and promote weight
loss. The contractor will be responsible for full deployment, onboarding, ongoing support,
and secure handling of Patient Generated Data in alignment with VA requirements.
Throughout the pilot, key outcomes—including weight change, metabolic indicators, user
engagement, and adherence—will be monitored to generate a comprehensive evaluation.
The findings will inform the VA’s understanding of clinical impact, total cost per participant,
and comparative value relative to GLP-1 therapies, supporting data-driven decisions
regarding potential future adoption or expansion.
Scope
The purpose of this effort is to pilot and evaluate the Continuous Glucose Monitoring
technology with an AI driven mobile application platform as a non-pharmacological
solution for weight management and metabolic health among Veterans. The contractor
shall provide all necessary personnel, equipment, software, and support services to deploy
and operate a solution that combines Continuous Glucose Monitoring (CGM) devices with
an AI-driven mobile application. The platform must enable real-time tracking of glucose
response to food and deliver actionable insights to support behavior change and weight
loss. The pilot will focus on Veterans who are not eligible for, have not responded to, or
prefer to avoid pharmacologic treatments such as GLP-1 receptor agonists. The contractor
shall ensure full deployment, participant onboarding, ongoing support, and secure
collection of Patient Generated Data in accordance with VA requirements. Throughout the
period of performance, the contractor shall monitor and report on key outcomes, including
weight change, metabolic indicators (as available), user engagement, and adherence. At
the conclusion of the pilot, the contractor shall provide a comprehensive evaluation that
includes clinical outcomes, total cost per participant, and a cost-benefit comparison
against GLP-1 treatment approaches, along with clear, data-driven recommendations
regarding scalability and potential adoption within the VA system.
-- 1 of 2 --
Data
The Vendor shall provide participant onboarding and access to the Continuous Glucose
Monitoring technology with an AI driven mobile application platform. During onboarding,
the Vendor shall collect only the participant information necessary to establish user
accounts and activate the Continuous Glucose Monitor (CGM) device. The platform shall
collect and store participant-generated health data (PGHD), including CGM readings and
participant-entered wellness information such as meals, exercise, sleep, and weight, for
the purpose of providing metabolic health insights and coaching. The Vendor shall protect
all participant information in accordance with applicable privacy, security, and contractual
requirements. The Continuous Glucose Monitoring technology with an AI driven mobile
application platform shall not connect to VA information systems or the VA Electronic
Health Record (EHR), and no VA clinical data shall be transmitted to or accessed by the
Vendor. All information collected by the platform shall be provided directly by participating
Veterans.
Based upon a review of the PWS/SOW and Appendix A as presented, the contractor will not
have access to VA sensitive information or PII/PHI to fulfill the terms of the contract. A BAA will
not be required.
-- 2 of 2 --
Source: SAM.gov, as posted. Verify the current solicitation before responding.